Drugs / Ursa
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT07005752 Comparator | Jul 2025 → Jun 2026 overdue | cholelithiasis | Myungmoon Pharma. Co. Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ursa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07005752 ↗ |
| Known as | Ursa tablet | “Ursa tablet(Ursodeoxycholic Acid) and CnU placebo capsule will be orally administered three times a day after meals at regular intervals for a total of 24 weeks.” NCT07005752 ↗ |